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Abstract: Black mulberry is a widely acknowledged ancient traditional medicine. Its extract and
constituents have been reported to exert various bioactivities including antimicrobial, hypotensive,
analgesic etc. effects. While black mulberry preparations are also used as antispasmodic agents in
folk medicine, no related studies are available on its isolated constituents. Through an extensive
chromatographic purification, seven phenolic compounds were isolated from the methanol extract of
Morus nigra root bark, including morusin (1), kuwanon U (2), kuwanon E (3), moracin P (4), moracin
O (5), albanol A (6), and albanol B (7). A complete NMR signal assignment of moracin P and O
was achieved, and related literature errors confusing the identity of moracin derivatives are hereby
clarified. Compounds 2, 5 and 7 were identified as strong antispasmodic agents on isolated rat ileum
and tracheal smooth muscles, while compound 3, a methoxy derivative of 2, was inactive. Moracin O
(5) inhibited the ileal and tracheal smooth muscle contractions with Emax values of 85% and 302 mg,
respectively. Those actions were superior as compared with papaverine. Our findings demonstrate
that prenylated arylbenzofurans, geranylated flavonoids and Diels-Alder adducts from Morus nigra
are valuable antispasmodic agents. Compounds 2, 5 and 7 are suggested as marker compounds for
quality control of antispasmodic mulberry preparations. Moracin O (5) is a new lead compound for
related drug development initiatives.
Keywords: mulberry polyphenol; prenylflavonoid; arylbenzofuran; gastrointestinal disorder;
asthma; spasmolytic
1. Introduction
Antispasmodics are widely used to treat conditions involving impaired contraction and relaxation
of smooth muscles in order to relieve muscle spasms, breathing problems, gastrointestinal cramps,
movement disorders, etc. [1]. Airway smooth muscles are responsible for the acute constriction
of the trachea and bronchi in asthma [2]. Concerning gastrointestinal smooth muscle contractility,
it represents the key mechanism involved in the pathophysiology of several gastrointestinal disorders
including irritable bowel syndrome (IBS) [3]. Therefore, antispasmodics play an important role in the
pharmacotherapy of such diseases. Considering the development of tolerance to present drugs and
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their potential adverse effects [4,5], the search for new antispasmodics that can act as bronchodilator
agents and/or gastrointestinal smooth muscle relaxants are of great interest. In this context, the relaxant
effect on airway and gastrointestinal smooth muscle has been reported for several medicinal plants,
including the black mulberry [6,7].
Morus nigra L. (Moraceae), commonly known as the black mulberry, is cultivated worldwide
for its nutritional, industrial and medicinal value. [8] According to a comparative study, M. nigra L.
has the highest amount of total phenolic and flavonoid content as compared to other Morus species
such as the white (M. alba L.) and the red (M. rubra L.) mulberry [9]. The root bark of M. nigra is
a particularly rich source of prenylated phenolic compounds [10]. The medicinal properties of M.
nigra have been valued since ancient times. In Greek and Ayurvedic medicines, preparations of this
plant have been used in various disorders involving the gastrointestinal tract (dyspepsia, diarrhea
and constipation) or the airways (sore throat, asthma and bronchitis), and also for the treatment of
hypertension [11–13]. In India, the black mulberry plant is an active constituent for many Unani and
ayurvedic medicines as mentioned in the ayurvedic pharmacopeia [14,15]. It can be used either as a
single drug or a component of complex preparations to treat different disorders, such as for example
“Tut-i-aswad”, an Unani medicine for cancer that contains the fruit of black mulberry [16]. “Rub-e-toot
siyah”, an ayurvedic remedy made from the root bark, is widely used for sore throat or laryngitis [17].
Almost all parts of the plant are used in the folk medicine, including treatment of hepatic [18] and
cardiovascular diseases [19], and as a diuretic [20], analgesic and hypoglycemic agent [21].
The aim of the present study was to investigate the possible smooth muscle relaxant activity of M.
nigra root bark extract and its constituents through a multi-step chromatographic purification of the
compounds and testing their antispasmodic effect on isolated rat trachea and ileum.
2. Results and Discussion
2.1. Isolation and Structure Elucidation of Compounds 1–7
The root bark of Morus nigra is a rich source of bioactive phenolic compounds [10]. In this study, a
multi-step chromatographic process was utilized for the isolation of such compounds. This process
included a combination of various techniques with different selectivity. The purification was started
by using polyamide column chromatography that is particularly efficient in separating phenolic
compounds from those with alcoholic hydroxyl groups [22], and this was followed by normal- and/or
reverse-phase flash chromatography, and reverse-phase HPLC. Seven phenolic compounds (1–7) were
obtained as shown in Figure 1.
Figure 1. Procedure of isolating phenolic compounds from the root bark of Morus nigra. F numbers
represent the corresponding fractions as detailed in the Materials and Methods, Section 3.3. LLE:
liquid-liquid extraction), CC: column chromatography, FC-NP: flash chromatography on normal phase,
FC-NP (flash chromatography on reverse phase, RP-HPLC: reverse-phase HPLC.
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Structure elucidation of compounds 1–3 and 6–7 was straightforward through comparing their
high-resolution electrospray ionization mass spectrometry (HRESIMS) and/or 1H- and 13C-NMR
data with published literature values [23–27]. However, when comparing the NMR chemical shifts
of compounds 4 and 5 with literature data, we found some contradictory spectral data concerning
moracin P and two related arylbenzofuran derivatives, moracins Q and R. In the paper reporting the
first isolation of moracins Q and R [28], chemical shifts of the prenyl-originated dimethyldihydropyran
ring of moracin Q, i.e., the dimethoxy derivative of moracin P, were assigned as nearly identical to
those previously reported for the substituted dihydrofuran ring of moracin O [25]. Further, the same
paper [28] reported chemical shifts of the prenyl side-chain of moracin R nearly identical to those
previously published for the analogous prenyl-originated ring of moracin P [25].
First, we attempted to clarify this through HRESIMS, but both compounds 4 and 5 showed the
same elemental compositions, i.e., C19H18O5. Considering that both moracins P and O may be formed
from moracin R by a water elimination, this may still have meant that the molecular ion of moracin
R could not be observed. It is worth noting that moracin R was reported with high-resolution mass
spectral data referring to the [M − H2O]+ m/z value [28].
Compound 4 was obtained as a brown amorphous powder. The molecular formula was determined
as C19H18O5 by HRESIMS. Signal assignment of the 1H-NMR spectrum (Figure S1) revealed the presence
of a disubstituted 2-arylbenzofuran moiety, a trisubstituted 2,2-dimethyldihydropyran ring and a
1,3,5-trisubstituted benzene ring. The 13C APT (attached proton test) measurement (Figure S2) showed
16 signals corresponding to 18 carbon atoms, including two methyl, one methylene, one sp3 oxymethyne
and one sp3 quaternary carbon, and in the sp2 region further six methyne, three quaternary carbon
and five oxyaryl carbon atoms. The HSQC experiment (Figure S3) revealed the one-bond 1H/13C
connections, while the HMBC measurement (Figure S4) allowed the assignment of the quaternary
carbon atoms through the 2JH,C and 3JH,C couplings. Based on the above spectroscopic evidence,
compound 4 was unambiguously identified as moracin P. Therefore, previous assignment of the
structure of this compound was correct [25], and this conclusion is also supported by reports on other
moracin P derivatives [29–31].
The condensed dimethyldihydropyran ring of moracin P (4) appeared in an equilibrium of two
half-chair conformations where C-2” and C.3” were the atoms out of the plane. The unambiguous
identification of the chemical shifts of the cis and trans located methyl/methine hydrogens was achieved
utilizing the two-dimensional NOESY measurement (τmixing = 300 ms) (SP-5). The 2.83/1.28 cross-peak
assigned that in the preferred conformation H-1”/CH3 (δ = 1.28) were cis and took the 1”/3” diaxial
position. The 3J(Htrans-1”,H-2”) > 3J(Hcis-1”, H-2”) values (7.6 Hz/5.2 Hz) supported the preference of
the depicted conformation (Figure S5).
Compound 5 was obtained as a brown amorphous powder. The molecular formula was
determined, also in this case, to be C19H18O5 by HRESIMS. The 1H (Figure S6) and 13C APT (Figure
S7) NMR spectra exhibited rather similar signals as obtained for 4, indicating that they should be
structural isomers. The spectra suggested the presence of a disubstituted 2-arylbenzofuran moiety and
a 1,3,5-trisubstituted benzene ring. Considering the heteronuclear multiple bond correlations (HMBC)
of the δ H-2” (4.64 ppm) atom with the δ C-5 (125.2 ppm) and δ C-6 (160.0 ppm), the third ring of
compound 5 was a condensed dihydrofuran ring substituted with a 1-methyl-1-hydroxyethyl group
(HO-C(Me2)-), suggesting that this compound should be moracin O. The NMR signal assignment was
also supported by the heteronuclear single quantum coherence (HSQC) (Figure S8), HMBC (Figure S9)
and NOESY (Figure S10) spectra. It needs to be stressed that NMR measurements taken in CD3OD,
or in other solvents where no separated OH signals can be observed, provide no information on the
number of the OH groups. To overcome this uncertainty, we have taken the NMR investigations (1H,
13C, edited HSQC, and HMBC, see Figures S11–S14) of compound 5 also in DMSO-d6.
A clear differentiation between moracin O and moracin R (5a) can be accomplished by detecting
the OH signals in the 1H-NMR spectrum: moracin R contains five, whereas Moracin O only three OH
groups. In the 1H spectrum, two new singlets appeared at δ 9.43 (2H) and 4.63 (1H), and these did
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not give HSQC cross-peaks (Figure S13), justifying the presence of three hydroxyl groups. Since the
values of 1H and 13C chemical shifts slightly changed in DMSO-d6 as compared to those observed
in CD3OD, HSQC and HMBC experiments were also performed to establish a complete 1H and
13C signal assignment. The limited resolution in the F1 dimension (13C) of the routine HMBC
experiment (optimized for JC,H = 8 Hz long-range couplings) did not allow the confident assignment
of several quaternary 13C signals. To achieve the required extremely high 13C chemical shift resolution,
the band-selective HMBC experiment was the method of our choice (see the upper part in Figure S14).
The 9.43/158.8 ppm cross-peak assigned the 3′,5′-OH positions and the exact δ C-3′,5′ chemical shifts,
differentiating from the rather closely appearing C-6 (δ 158.3) peak. With the aid of the well separated
HMBC cross-peaks 6.66/154.1 and 7.34/154.2 ppm, respectively, the unambiguous assignment of the δ
C-2 and δ C-7a values became possible. Based on the above, compound 5 was clearly identified as
moracin O. As for the contradictory literature data, this also suggests that the compound reported
as moracin Q is likely the dimethoxy derivative of moracin O instead of that of moracin P. Further,
the chemical shifts reported for moracin R suggest a possible false assignment of the structure of this
compound that was moracin P instead [28].
Compounds 4 and 7 are reported here for the first time from the root bark of M. nigra, whereas the
presence of other compounds was previously reported [32,33]. Chemical structures of compounds 1–7,
as well as that of moracin R (5a), are presented in Figure 2.
Figure 2. Phenolic compounds isolated from the root bark of Morus nigra. These are morusin (1),
kuwanon U (2), kuwanon E (3), moracin P (4), moracin O (5), albanol A (6), and albanol B (7). Moracin
R (5a) is presented only for comparison purposes as a ruled-out alternative structure for compound 5;
compound 5a was not isolated in this study. Atomic numbering is presented for moracin P (4) and
moracin O (5).
2.2. Antispasmodic Activity of Compounds 1–7
As a first screening, a 3-points assay was performed that was an appropriate experimental setup
for the identification of active compounds, but it was not precise enough to determine the affinity (EC50)
and efficacy (Emax). In this preliminary bioassay, the crude extract and most of the solvent-solvent
extracted fractions of Morus nigra root bark elicited a slight contracting effect (i.e., negative action) or
no effect at all. These results suggest that the root bark of Morus nigra may contain constituents with
smooth muscle contracting activity that mask the potent smooth muscle relaxing effect of some of the
isolated compounds (see below). Morusin (1), kuwanon E (3), moracin P (4) and albanol A (6) had
only non-significant relaxing activity (or no action) on the rat ileal contractions. Additionally, except
for albanol A, these compounds elicited a very moderate tracheal tone reducing effect that was much
lower than that of papaverine. However, a remarkable activity was found for kuwanon U (2), moracin
O (5) and albanol B (7) on both experimental models (Table 1), therefore these compounds were further
studied for their efficacy.
Molecules 2019, 24, 2497 5 of 12
Table 1. Activity of the crude extract, pre-purified fractions and purified constituents of Morus nigra
L. in a 3-point assay on isolated rat ileum and trachea. Papaverine was used as a positive control.
The extract and fractions were administered at 0.01, 0.03 and 0.1 mg/mL, and the pure compounds at
10−8, 10−7 and 10−6 M concentrations.
Compound Maximal Inhibition of Ileal Contraction(%) Tracheal Tone Reduction (mg)
papaverine a 47.9 ± 10.5 134.4 ± 41.4
MeOH extract −33.2 ± 27.9 *** −22.0 ± 11.9 ***
EtOAc fraction 24.4 ± 16.2 ** −5.0 ± 11.9 ***
n-Hexane fraction no action no action
Water fraction −9.1 ± 10.8 *** −32.5 ± 10.3 ***
morusin (1) no action 90.7 ± 20.4 *
kuwanon U (2) a 39.6 ± 4.5 145.5 ± 16.7
kuwanon E (3) 26.6 ± 9.1 * no action
moracin P (4) no action 42.4 ± 7.7 **
moracin O (5) a 47.2 ± 11.6 123.6 ± 36.1
albanol A (6) 20.5 ± 9.1 ** 194.7 ± 42.3 *
albanol B (7) a 35.5 ± 8.4 100.6 ± 43.6 *
a Compounds involved in further experiments due to their significant activity on both types of smooth muscle
(criterion set as >30% inhibition of ileal contraction and >100 mg reduction in the tracheal tone). The negative
actions mean contracting effect. Papaverine was used as a positive control on both experimental models. *p < 0.05,
**p < 0.01 and ***p < 0.001 as compared to the effect of papaverine by means of one-way ANOVA followed by
Tukey’s post-hoc test.
Remarkably, the 8-points assay on the inhibition of ileal contractions revealed that compounds 2, 5
and 7 were equipotent with papaverine with respect to their EC50 values in both experimental models.
Furthermore, each of these compounds showed a tendency for a higher Emax value on ileal contraction
than that of papaverine, and in the case of moracin O (5), this was also statistically significant. With
respect to the compounds’ activity on the tracheal tone, similar results were obtained. The three
studied compounds exerted their 50% activity at the same, low nanomolar concentration range as
papaverine. Furthermore, moracin O (5) exerted a significantly stronger maximum decrease in the
tracheal tone as compared to papaverine. Dose–response curves and calculated numerical results of
these experiments are presented in Figure 3 and Table 2.
Figure 3. Concentration–response curves of compounds 2, 5 and 7 on the ileal contractions (A) and
tracheal tone (B) of isolated rat smooth muscles. Papaverine was used as a positive control. All the
compounds elicited a relaxing effect on ileal smooth muscle.
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Table 2. Smooth muscle relaxant activity of compounds 2, 5 and 7 on isolated rat ileum and trachea.
EC50 and Emax values on the ileal contractions and tracheal tone are presented. Papaverine was used
as a positive control on both experimental models.
Compound Ileal Contractions Tracheal Tone
EC50 ± SEM (µM) Emax ± SEM (%) EC50 ± SEM (µM) Emax (mg ± SEM)
kuwanon U (2) 0.13 ± 0.04 70.5 ± 6.1 0.033 ± 0.05 247.8 ± 9.9
moracin O (5) 1.1 ± 0.43 85.3 ± 4.4* 0.062 ± 0.01 309.5 ± 17.7 *
albanol B (7) 1.3 ± 0.98 83.2 ± 3.9 0.100 ± 0.05 254.9 ± 19.3
papaverine 0.44 ± 0.15 63.6 ± 6.3 0.074 ± 0.03 233.7 ± 15.4
*p < 0.05 as compared to the effect of papaverine by means of one-way ANOVA followed by Tukey’s post-hoc test.
To the best of our knowledge, this is the first report of the smooth muscle relaxant activity of
compounds 2, 5, and 7. This bioactivity of each of these compounds is of high potential therapeutic
interest: kuwanon U (2) and albanol B (7) were found equipotent with the opium alkaloid antispasmodic
drug papaverine (i.e., no statistically significant differences were found between them), and moracin O
(5) exerted an even stronger effect than that.
Vasorelaxant activity of several prenylated phenolic compounds has previously been reported,
but much higher concentrations typically in the medium-low micromolar range were needed for a
50% relaxation [34,35]. An extract of the prenylflavone-containing hops was reported to exert relaxant
activity on rat ileum contractions ex vivo, but since the extracting solvent was water, it is unlikely that
the active constituents were prenylated phenolics [36].
Despite the widely available options for antispasmodic therapy, there has been an increase in
complaints related to bowel motility and bronchial asthmatic problems [37,38]. Therefore, there is
an emerging need to find new, effective and safe, possibly natural drugs for the treatment of such
disorders. The potent antispasmodic compounds presented in this work may open the way towards
potential new therapeutic alternatives to the existing treatments.
3. Materials and Methods
3.1. General
Column chromatography (CC), flash chromatography (FC), and thin layer chromatography (TLC)
were performed on polyamide SC6 (50–160 µm, Macherey-Nagel GmbH and Co., Düren, Germany),
silica gel 60 (45–63 µm, Molar Chemicals, Halásztelek, Hungary), and silica gel 60 F254 or RP-18 F254S
(250 µm, Merck Co., Darmstadt, Germany), respectively. TLC was used at each chromatographic step to
monitor the separation with a solvent system of toluene–ethyl acetate–formic acid (5:4:1, v/v/v), and the
spots were detected under UV light (λ1 = 254 nm, λ2 = 365 nm) and daylight after spraying with 5%
H2SO4 in ethanol followed by heating. HPLC analysis was performed on a Jasco 2010 series instrument
equipped with a Jasco PU-2080 quaternary pump, a vacuum degasser, an AS-2055Plus intelligent
autosampler and a Jasco MD-2010 Plus photodiode array detector (Jasco Co., Tokyo, Japan). Melting
points were determined on a Boetius apparatus (VEB Analytik Dresden, Dresden, Germany). Organic
solvents used for TLC, FC and CC (analytical grade) were purchased from Sigma-Aldrich (Budapest,
Hungary), and HPLC solvents were purchased from Avantor Performance Materials (Gliwice, Poland).
Papaverine was purchased from Takeda Pharma Ltd. (Budapest, Hungary).
3.2. Plant Material, Extraction and Pre-Purification
Root bark (590 g) of Morus nigra was collected from a farm nearÁsotthalom, Hungary, in December
2013. After air-drying, a voucher specimen was deposited in the Institute of Pharmacognosy, University
of Szeged, Szeged, Hungary. The plant material was ground into a coarse powder and extracted
with MeOH (3 × 4 L) at room temperature. After evaporation of methanol under vacuum at 40 ◦C,
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the residue (92.7 g) was diluted with 18% of MeOH. Following this, the crude extract was subjected to
solvent-solvent distribution, first with n-hexane (5 × 500 mL), and then with ethyl acetate (5 × 500 mL)
to produce n-hexane (7.3 g), ethyl acetate (54.1 g) and water (36.7 g) fractions. Ethyl acetate fraction
was further processed due to its higher amount and chemical complexity.
3.3. Chromatographic Separation of Compounds 1–7
Column chromatographic separation of compounds was performed in a glass column (162 cm ×
5.5 cm). The column was packed with 500 g polyamide and the ethyl acetate layer of the crude extract
was subjected to the column through dry loading technique by adsorbing it on polyamide (100 g). A
stepwise gradient of ethyl acetate and mixtures of ethyl acetate–methanol (95:5, 9:1, 8:2 and 7:3, v/v)
was utilized for the separation. The eluates were evaporated under vacuum to obtain 258 fractions,
and fractions were joined according to their TLC fingerprints to afford a total of 56 joint fractions that
were subsequently further purified by flash chromatography and HPLC.
Flash chromatography was performed for fractions 7, 13, 20 and 25 on a CombiFlash Rf+ Lumen
instrument equipped with an integrated evaporative light scattering detector (ELSD) (Teledyne Isco,
Lincoln, NE, USA). Fraction 7 (10 g) was purified on a silica gel column (80 g) gradually eluted with
n-hexane–ethyl acetate to afford 24 subfractions giving pure compound 1 (1.98 g) from the subfraction
10, and the subfraction 17 was purified by preparative HPLC (Waters Co. Milford, MA, USA), using
ACN–H2O (7:3, v/v) as a mobile phase, leading to the isolation of compound 2 (85 mg). The column
fraction 13 (1.27 g) underwent reverse phase chromatography over polyamide column (13 g polyamide)
by using dry loading on cellite (20–100 µm), with a stepwise gradient of aqueous MeOH as an eluting
agent through flash in order to obtain nine subfractions affording pure compound 3 (60 mg) from the
6th flash fraction, whereas subfraction 8 was purified over RP-HPLC on a C18 (5 µm, 250 × 21.2 mm)
column with an isocratic elution of ACN–H2O (1:1, v/v). The purified fraction (75 mg) was further
separated on a Biphenyl (5 µm, 250 × 21.2 mm) column with the help of preparative HPLC using
MeOH–H2O (57:43, v/v) to acquire compounds 4 (30 mg) and 5 (35 mg). Fraction 20 (1.25 g) was
purified over polyamide through reverse-phase flash chromatography with aqueous MeOH as the
mobile phase, and subfraction 5 was further purified on a C18 column using ACN–H2O (5:5, v/v) to
get compound 6 (120 mg). Fraction 25 (1.21 g) was gradually eluted with aqueous MeOH to obtain
compound 7 (180 mg) through reverse phase flash chromatography using polyamide column. After the
solvent was evaporated, the purified compounds were stored in a refrigerator until further analysis.
The relative purity of each isolated compound was examined by HPLC using a C18 column with
a flow rate of 1.0 mL/min, with an isocratic elution of ACN–H2O (1:1, v/v), and 20 µL of each sample
was injected.
3.4. Structure Elucidation of the Isolated Compounds
Structure determination of the isolated compounds was carried out by one- (1H, 13C, APT) and
two-dimensional (HSQC, HMBC, 1H,1H-COSY, NOESY) NMR spectroscopic methods. NMR spectra
were recorded at room temperature in methanol-d4 on Bruker Avance DRX 500 and NEO spectrometers,
however, for compound 5, the 600/150 MHz spectra were taken in dimethylsulfoxide-d6 on a Bruker
Avance III 600 MHz spectrometer equipped with Prodigy cryo-probe head. Chemical shifts (δ) are
given on the δ-scale and referenced to the solvents (methanol-d4: δH = 3.31 and δC = 49.1 ppm,
and dimethylsulfoxide-d6: δH = 2.50 and δC = 39.5 ppm) and coupling constant (J) values are expressed
in Hz. Pulse programs of all experiments [1H, 13C, APT, gs-HSQC, edited gs-HSQC, gs-HMBC
(optimized for 7 Hz), band-selective gs-HMBC and NOESY (mixing time = 300 ms)] were taken from
the Bruker software library. The NMR signals of the products were assigned by comprehensive one- and
two-dimensional NMR methods using widely accepted strategies [39,40]. Most 1H assignments were
accomplished using general knowledge of chemical shift dispersion with the aid of the proton–proton
coupling pattern (1H-NMR spectra). High-resolution mass spectra (HRESIMS) were recorded on a
Thermo Scientific Q Exactive Plus orbitrap mass spectrometer equipped with a HESI-II ion source
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(Waltham, MA, USA). Samples were applied by using flow injection by a Thermo Dionex Ultimate
3000 HPLC system. The eluent was water–acetonitrile (1:1, v/v) mixture containing 0.1% formic acid,
the flow rate was 200 µL/min, and 5 µL of the sample was injected. The ion source parameters were set
as follows: nebulizer gas flow: 10, auxiliary gas: 18, sheath gas: 3, all in arbitrary units, the auxiliary gas
temperature was 400 ◦C, and the ion transfer capillary temperature was 300 ◦C. Theoretical m/z values
for the [M + H]+ molecular ions were calculated by ChemDraw 12.0 (CambridgeSoft, Cambridge, MA,
USA). HRESIMS spectra of compounds 1–5 are provided as Supplementary Materials, Figures S15-S19.
Morusin (1): yellow solid [23]; 1H-NMR (CD3OD, 500 MHz) δ 7.10 (1H, d, J = 8.2 Hz), 6.58 (1H, d,
J = 10.0 Hz), 6.42 (1H, br s), 6.40 (1H, br d, J = 8.2 Hz), 6.14 (1H, s), 5.57 (1H, d, J = 10.0 Hz), 5.09 (1H, br
t, J = 6.9 Hz), 3.10 (2H, d, J = 7.3 Hz), 1.59 (3H, s), 1.43 (6H, s), 1.40 (3H, s); 13C-NMR (CD3OD, 125
MHz) δ 183.9, 163.6, 162.7, 162.1, 160.5, 158.0, 153.8, 132.9, 132.5, 128.2, 122.7, 122.1, 115.8, 113.1, 108.0,
105.9, 103.8, 102.2, 100.1, 79.1, 2 × 28.4, 25.9, 24.9, 17.7. HRESIMS: C25H24O6 ([M + H]+ calcd. m/z:
421.16511, found m/z: 421.16407).
Kuwanon U (2): yellow solid [26]; 1H-NMR (CD3OD, 500 MHz) δ 7.13 (1H, s), 6.43 (1H, s), 5.91 (1H,
br s), 5.88 (1H, br s), 5.62 (1H, br d, J = 12.3 Hz), 5.24 (1H, br t, J = 7.0 Hz), 5.08 (1H, br t, J = 6.0 Hz),
3.78 (3H, s), 3.19 (2H, d, J = 7.2 Hz), 3.02 (1H, dd, J = 17.0 and 13.5 Hz), 2.70 (1H, br d, J = 17.0 Hz), 2.08
(2H, m), 2.01 (2H, m), 1.67 (3H, s), 1.61 (3H, s), 1.55 (3H, s). 13C-NMR (CD3OD, 125 MHz) δ 198.3, 168.3,
165.5, 165.3, 159.5, 154.7, 136.4, 132.1, 128.4, 125.4, 124.4, 122.1, 117.8, 103.4, 99.6, 96.9, 96.2, 75.9, 55.8,
43.1, 40.8, 28.6, 27.8, 25.9, 17.8, 16.2. HRESIMS: C26H30O6 ([M + H]+ calcd. m/z: 439.2121, found m/z:
439.2112).
Kuwanon E (3): yellow solid [24]; 1H-NMR (CD3OD, 500 MHz) δ 7.07 (1H, s), 6.34 (1H, s), 5.91 (1H,
br s), 5.88 (1H, br s), 5.62 (1H, br d, J = 12.3 Hz), 5.30 (1H, br t, J = 6.6 Hz), 5.11 (1H, m), 3.20 (2H, d,
J = 7.1 Hz), 3.05 (1H, dd, J = 17.0 and 12.8 Hz), 2.70 (1H, br d, J = 17.0 Hz), 2.09 (2H, m), 2.02 (2H, m),
1.68 (3H, s), 1.62 (3H, s), 1.56 (3H, s); 13C-NMR (CD3OD, 125 MHz) δ 198.5, 168.3, 165.5, 165.4, 157.0,
154.4, 136.5, 132.1, 128.7, 125.4, 124.4, 120.6, 117.3, 2 x 103.4, 96.9, 96.2, 76.1, 43.2, 40.9, 28.5, 27.8, 25.9,
17.8, 16.2. HRESIMS: C25H28O6 ([M + H]+ calcd. m/z: 425.16941, found m/z: 425.19619).
Contradictory data have been published concerning the NMR chemical shifts of moracins P, R
and O, and this may lead to a mistaken identification of these. Therefore, we present all relevant NMR
spectra for compounds 4 and 5 as Supplementary Material, Figures S1-S14.
Moracin P (4): brown solid [25]; m.p. 252–254 ◦C; 1H-NMR (CD3OD, 500 MHz) δ 7.23 (1H, s, H-4), 6.89
(1H, s, H-3), 6.86 (1H, s, H-7), 6.75 (2H, d, J = 2.1 Hz, H-2′,6′), 6.24 (1H, br t, J = 2.0 Hz, H-4′), 3.79 (1H,
dd, J = 7.6 and 5.2 Hz, H-2”), 3.12 (1H, dd, J = 16.5 and 5.2 Hz H-1”a), 2.83 (1H, dd, J = 16.5 and 7.6 Hz
H-1”b), 1.36 (3H, s, H-5”), 1.28 (3H, s, H-4”); 13C-NMR (CD3OD, 125 MHz) δ 160.1 (C-3′,5′), 156.7 (C-2),
156.0 (C-7a), 152.7 (C-6), 133.8 (C-1′), 124.3 (C-3a), 121.9 (C-4), 117.8 (C-5), 104.1 (C-2′,6′), 103.7 (C-4′),
101.9 (C-3), 99.8 (C-7), 78.3 (C-3”), 70.7 (C-2”), 32.5 (C-1”), 26.1 (C-5”), 21.2 (C-3”). HRESIMS: C19H18O5
([M + H]+ calcd. m/z: 327.1232, found m/z: 327.1230).
Moracin O (5): brown solid [25]; m.p. 235–236 ◦C; 1H-NMR (CD3OD, 500 MHz) δ 7.29 (1H, s, H-4), 6.89
(1H, s, H-3), 6.85 (1H, s, H-7), 6.74 (2H, d, J = 2.1 Hz, H-2′,6′), 6.23 (1H, br t, J = 2.1 Hz, H-4′), 4.64 (1H,
t, J = 8.6 Hz, H-2”), 3.22 (2H, m, H2-1”), 1.28 (3H, s, H-4”), 1.24 (3H, s, H-5”); 13C-NMR (CD3OD, 125
MHz) δ 160.1 (C-3′,5′), 160.0 (C-6), 156.5 (C-7a), 156.3 (C-2), 133.9 (C-1′), 125.2 (C-5), 124.1 (C-3a), 117.1
(C-4), 103.9 (C-2′,6′), 103.5 (C-4′), 102.5 (C-3), 93.3 (C-7), 91.5 (C-2”), 72.6 (C-3”), 31.3 (C-1”), 25.4 (C-4”),
25.5 (C-5”). 1H-NMR (DMSO-D6, 600 MHz) δ 9.43 (2H, s, HO-3′,5′), 7.34 (1H, s, H-4), 7.07 (1H, s, H-3),
6.97 (1H, s, H-7), 6.66 (2H, d, J = 2.1 Hz, H-2′,6′), 6.19 (1H, t, J = 2.1 Hz, H-4′), 4.63 (1H, s, HO-3”),
4.60 (1H, dd, J = 9.3 and 8.3 Hz, H-2”), 3.20 (1H, dd, J = 15.7 and 8.3 Hz, Ha-1”), 3.15 (1H, dd, J = 15.7
and 9.3 Hz, Hb-1”),1.144 (3H, s, H-5”), 1.137 (3H, s, H-4”); 13C-NMR (DMSO-D6, 150 MHz) δ 158.8
(C-3′,5′), 158.3 (C-6), 154.2 (C-7a), 154.1 (C-2), 131.7 (C-1′), 124.2 (C-5), 121.8 (C-3a), 116.1 (C-4), 102.5
(C-4′), 102.1 (C-2′,6′), 101.7 (C-3), 92.2 (C-7), 90.0 (C-2”), 70.1 (C-3”), 29.5 (C-1”), 26.1 (C-4”), 24.8 (C-5”).
HRESIMS: C19H18O5 ([M + H]+ calcd. m/z: 327.1232, found m/z: 327.1227).
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Albanol A (6): yellow solid [27]; 1H-NMR (CD3OD, 500 MHz) δ 7.33 (1H, d, J = 8.4 Hz), 7.12 (1H, d,
J = 8.7 Hz), 7.08 d (1H, d, J = 8.4 Hz), 6.91 (1H, s), 6.89 (1H, br s), 6.88 (1H, br s), 6.81 (1H, br s), 6.72 (1H,
dd, J = 8.4 and 1.3 Hz), 6.44 (1H, dd, J = 8.4 and 1.8 Hz), 6.40 (1H, br s), 6.33 (1H, d, J = 1.8 Hz), 6.31
(1H, d, J = 1.7 Hz), 6.13 (1H, dd, J = 8.7 and 1.7 Hz), 3.33 (1H, overlapped with w signal), 3.31 (1H,
overlapped with solvent signal), 2.94 (1H, ddd, J = 11.5 and 11.0 and 5.0 Hz), 2.66 (1H, dd, J = 16.9 and
5.0 Hz), 2.00 (1H, dd, J = 16.9 and 11.0 Hz), 1.78 s (3H, s); 13C-NMR (CD3OD, 125 MHz) δ 160.1, 158.4,
157.9, 157.8, 157.3, 156.8, 155.7, 154.9, 153.6, 133.9, 131.5, 130.6, 128.0, 123.4, 123.1, 122.0, 118.3, 117.4,
113.9, 113.2, 110.0, 107.0, 105.5, 105.0, 104.5, 104.2, 103.1, 102.1, 98.5, 37.6, 36.7, 35.4, 28.8, 23.9.
Albanol B (7): dark brown solid [27]; 1H-NMR (CD3OD, 500 MHz) δ 8.38 (1H, s), 7.59 (1H, d, J = 8.3 Hz),
7.50 (1H, s), 7.33 (1H, d, J = 8.3 Hz), 7.01 (1H, br s), 6.99 (1H, br s), 6.95 (1H, s), 6.90 (1H, br s), 6.73 (1H,
dd, J = 8.3 and 1.9 Hz), 6.51 (1H, dd, J = 8.3 and 1.8 Hz), 6.47 (1H, br s), 6.26 (1H, d, J = 2.1 Hz), 6.13
(1H, d, J = 8.6 Hz), 5.85 (1H, dd, J = 8.6 and 2.1 Hz), 2.50 (3H, s); 13C-NMR (CD3OD, 125 MHz) δ 160.6,
160.0, 158.1, 2 × 157.3, 156.9, 155.0, 153.5, 152.6, 140.9, 132.6, 131.5, 130.0, 129.7, 126.6, 125.3, 123.0, 122.5,
122.3, 121.3, 115.9, 115.6, 113.4, 111.7, 111.5, 107.3, 106.6, 106.4, 106.0, 105.4, 104.9, 103.2, 98.5, 22.3.
3.5. Housing and Handling of the Animals
All experiments involving animal subjects were carried out with the approval of the National
Scientific Ethical Committee on Animal Experimentation (permission number: IV/198/2013).
The animals were treated in accordance with the European Communities Council Directives (2010/63/EU)
and the Hungarian Act for the Protection of Animals in Research (Article 32 of Act XXVIII).
Sprague-Dawley rats were maintained at 22 ± 3 ◦C, under a lights-darkness cycle of 12 h/12 h,
with a relative humidity of 30%–70%. The animals were fed with a standard rodent pellet diet (Innovo
Ltd., Isaszeg, Hungary), with tap water available ad libitum.
3.6. Isolated Organ Bath Studies
In isolated organ bath studies, male rats (160–200 g, n = 8) were used. The animals were starved
16 h before the experiment. On the day of measurement, rats were terminated by CO2 inhalation.
Distal ileum was dissected, cut into 5 mm long samples, and mounted vertically in an organ
bath containing 10 mL of Tyrode buffer (composition in mM: 137 NaCl, 3 KCl, 1 CaCl2, 1 MgCl2, 12
NaHCO3, 0.4 NaH2PO4, 6 glucose, pH 7.4), heated at 37 ◦C and carbogen (95% O2 + 5% CO2) was
bubbled through it. The initial tension of the ileum samples was set to about 1.5 g, the tissues were
equilibrated for about 60 min, and the buffer was changed in every 15 min. The regular contractions
were recorded for 5 min, and then 25 mM KCl was administered. The area under the curve (AUC) of
KCl evoked contractions was compared with the AUC of regular contractions. Papaverine was used as
a positive control.
After the esophagus and blood vessels were removed from trachea tissues, they were cut
transversally into 4–5 mm-wide rings, which were placed in 37 ◦C Krebs buffer (composition in
mM: 118 NaCl; 4.75 KCl; 2.5 CaCl2; 1.19 K2HPO4; 25 NaHCO3; 1.2 MgSO4 and 11 glucose, pH 7.4).
The tracheal rings were mounted with their longitudinal axis vertically by hooks and equilibrated
for 1 h, while the buffer solution was renewed in every 15 min. The initial strain was set to about
2.00 g. Papaverine was used as a positive control in the same concentration range as that of the
isolated compounds.
First, we carried out a 3-points assay (10−8, 10−7 and 10−6 M) to determine the approximate
activities of the compounds, then the compounds showing significant activity (i.e., maximum ileum
contraction inhibition higher than 30%, and tracheal tone reduction higher than 100 mg) were studied
further in an 8-points assay (10−8.5–10−5 M) obtaining cumulative concentration-response curves.
The concentrations eliciting the half of the maximum effect (EC50) and the maximum effects (Emax)
were calculated and statistically evaluated.
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The tracheal and ileal tissues activities were measured with a gauge transducer (SG-02, MDE Ltd,
Budapest, Hungary) and recorded with a SPEL Advanced ISOSYS Data Acquisition System (MDE Ltd,
Budapest, Hungary).
3.7. Statistical Analysis
All smooth muscle contractility data were analyzed by the Prism 5.01 (GraphPad Software, USA)
software. The data were statistically evaluated by ANOVA with a Tukey multiple comparison test that
is suitable to compare more than two groups. The Tukey multiple comparison test compares every
mean with every other mean, and for each dataset, we present statistically significant differences as
compared with the papaverine group.
4. Conclusions
Seven phenolic compounds were isolated from the root bark of Morus nigra. The structure
elucidation of compounds 4 and 5 revealed contradictory literature data that allow misidentification
and confusing the identities of moracin derivatives. Through a detailed NMR investigation, we have
unambiguously identified compound 4 as moracin P and compound 5 as moracin O, and provided
their complete NMR signal assignment in DMSO-d6 and/or CD3OD.
Subsequent to an ex vivo antispasmodic screening on rat ileal and tracheal smooth muscles, three
compounds were selected for a detailed investigation. Based on our results, compounds 2, 5 and 7
were identified as potential new antispasmodic agents. The affinity and efficacy of kuwanon U (2)
and albanol B (7) make these compounds equipotent with papaverine, and this would warrant their
further studies in intact animals. Most importantly, moracin O (5) was found superior to papaverine in
both smooth muscle organs. Accordingly, this compound was identified as a new lead molecule that
may be further developed to a potent new gastrointestinal or tracheal relaxant, and/or may serve as a
chemical starting point towards the development of a new class of spasmolytic drugs.
Supplementary Materials: NMR spectra of compounds 4 and 5, and HRESIMS spectra of compounds 1–5 are
provided as supplementary material. These can be found at http://www.mdpi.com/1420-3049/24/13/2497/s1,
Figures S1–S19.
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